Transcription and signalling pathways involved in BCR–ABL‐mediated misregulation of 24p3 and 24p3R

Lipocalin 24p3 is a secreted protein that can induce apoptosis in cells containing the 24p3 cell surface receptor, 24p3R. The oncoprotein BCR–ABL activates 24p3 and represses 24p3R expression. Thus, BCR–ABL+ cells synthesise and secrete 24p3, which induces apoptosis in normal 24p3R‐containing cells but not in BCR–ABL+ cells. The cell signalling and transcription factor pathways by which BCR–ABL misregulates expression of 24p3 and 24p3R remain to be elucidated. Here we show that BCR–ABL upregulates 24p3 expression through activation of the JAK/STAT pathway, which culminates in binding of Stat5 to the 24p3 promoter. We find that 24p3R expression is regulated by Runx transcription factors, and that BCR–ABL induces a switch in binding from Runx3, an activator of 24p3R expression, to Runx1, a repressor of 24p3R expression, through a Ras signalling pathway. Finally, we show that repression of 24p3R by BCR–ABL is a critical feature of the mechanism by which imatinib kills BCR–ABL+ cells. Our results reveal diverse signalling/transcription pathways that regulate 24p3 and 24p3R expression in response to BCR–ABL and are directly relevant to the treatment of BCR–ABL+ disease.

[1]  L. Hennighausen,et al.  Distinctive Roles of STAT5a and STAT5b in Sexual Dimorphism of Hepatic P450 Gene Expression , 1999, The Journal of Biological Chemistry.

[2]  D. Ayer,et al.  Histone deacetylases: transcriptional repression with SINers and NuRDs. , 1999, Trends in cell biology.

[3]  Christine Barett,et al.  Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. , 2006, Blood.

[4]  B. Druker,et al.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.

[5]  B. Druker,et al.  An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia , 2008, Leukemia.

[6]  J. Hancock,et al.  Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase* , 1998, The Journal of Biological Chemistry.

[7]  N. Liverton,et al.  Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. , 2002, Bioorganic & medicinal chemistry letters.

[8]  H. Kantarjian,et al.  Janus kinase 2: a critical target in chronic myelogenous leukemia. , 2006, Cancer research.

[9]  J. G. Teodoro,et al.  Induction of Apoptosis by a Secreted Lipocalin That is Transcriptionally Regulated by IL-3 Deprivation , 2001, Science.

[10]  P. Warne,et al.  Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.

[11]  H. Kantarjian,et al.  Important Therapeutic Targets in Chronic Myelogenous Leukemia , 2007, Clinical Cancer Research.

[12]  H. Kantarjian,et al.  Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. , 1989, Blood.

[13]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[14]  M. Copland,et al.  BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. , 2008, Blood.

[15]  B. Aggarwal,et al.  Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia , 2004, Cancer Research.

[16]  Alan Aderem,et al.  Lipocalin 2 is required for BCR-ABL-induced tumorigenesis , 2008, Oncogene.

[17]  H. Lin,et al.  BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor , 2008, Oncogene.

[18]  D. Levanon,et al.  Structure and regulated expression of mammalian RUNX genes , 2004, Oncogene.

[19]  Stephen Mackinnon,et al.  Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia. , 2003, The New England journal of medicine.

[20]  T. Skorski,et al.  Oncogenic tyrosine kinases and the dna-damage response , 2002, Nature Reviews Cancer.

[21]  Michael R. Green,et al.  A Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake , 2005, Cell.

[22]  P. A. Harris,et al.  The discovery of potent cRaf1 kinase inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[23]  E. Seto,et al.  A Mechanism of Repression by Acute Myeloid Leukemia-1, the Target of Multiple Chromosomal Translocations in Acute Leukemia* , 2000, The Journal of Biological Chemistry.

[24]  Michael R Green,et al.  HIV-1 Tat Stimulates Transcription Complex Assembly through Recruitment of TBP in the Absence of TAFs , 2005, PLoS biology.

[25]  M. Wigler,et al.  Structure and activation of the human N-ras gene , 1983, Cell.

[26]  T. Tauchi,et al.  Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia , 2004, International journal of hematology.

[27]  G. Daley,et al.  Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. , 2002, Blood.

[28]  J. Belmont,et al.  Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia , 2005, Oncogene.

[29]  F. E. Bertrand,et al.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.

[30]  J. Melo,et al.  Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. , 2004, Hematology/oncology clinics of North America.

[31]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[32]  M. Wigler,et al.  Multiple ras functions can contribute to mammalian cell transformation , 1995, Cell.

[33]  Matthew B. Wilson,et al.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells , 2002, The EMBO journal.

[34]  N. Donato,et al.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.

[35]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[36]  R. V. van Etten,et al.  P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members* , 1996, The Journal of Biological Chemistry.

[37]  N. Danial,et al.  JAK-STAT signaling activated by Abl oncogenes , 2000, Oncogene.

[38]  E. Nånberg,et al.  Role of phosphoinositide 3OH‐kinase in autocrine transformation by PDGF‐BB * , 2001, Journal of cellular physiology.

[39]  D. Frank,et al.  Isolation of Unique STAT5 Targets by Chromatin Immunoprecipitation-based Gene Identification* , 2004, Journal of Biological Chemistry.

[40]  Yusuke Nakamura,et al.  Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. , 2003, International journal of oncology.

[41]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[42]  J. Belmont,et al.  BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model , 2001, Oncogene.

[43]  A. Reiter,et al.  Tyrosine kinase fusion genes in chronic myeloproliferative diseases , 2002, Leukemia.

[44]  M. Barbacid ras genes. , 1987, Annual review of biochemistry.